FDA accepts BLA with priority review for Xiaflex, a treatment for Dupuytren’s disease

BioSpecifics Technologies announced that the FDA has accepted for filing and granted priority review of the Biologics License Application (BLA) submitted for Xiaflex. Xiaflex treats Dupuytren’s disease, a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers.

Xiaflex is a first in class collagenase-based product being co-developed by BioSpecifics and Auxilium Pharmaceuticals.

For more information call (516) 593-7000 or visit www.biospecifics.com.